Here are the 10-K annual reports from Synlogic Inc (SYBX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow SYBX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SYBX filings page.
Synlogic, Inc. filed an Amendment No. 1 to its Annual Report for the year ended December 31, 2025 to add the Part III disclosures that were intentionally omitted from the original filing. The amendment covers directors, governance, executive and director compensation, ownership, related-party policies and auditor fees.
The Board has four directors, all deemed independent, and the company reports having one full-time employee as of March 31, 2026, focused on strategic transactions. Principal Executive and Financial Officer Mary Beth Dooley received 2025 total compensation of $335,500, with no bonus or equity grants that year.
Funicular Funds and New Enterprise Associates 14 each hold more than 25% of Synlogic’s common stock, while several other investors exceed five percent. Audit fees paid to KPMG LLP for 2025 were $365,000, with additional tax fees. The filing also highlights insider trading controls, a clawback policy and equity incentive and director compensation programs.
Synlogic, Inc. files its annual report describing a transition from an operating biotech to a non‑operating public shell focused on pursuing strategic alternatives, including a potential merger or sale of the company. The shift follows the February 2024 decision to discontinue Synpheny‑3, the pivotal Phase 3 trial of lead PKU candidate SYNB1934, after an internal review indicated it was unlikely to meet its primary endpoint.
The company’s common stock was delisted from Nasdaq effective January 21, 2026, and now trades on the OTC Basic Market under the symbol SYBX, with related liquidity, penny‑stock and “blue sky” constraints highlighted as key risks. As of June 30, 2025, non‑affiliate market value of common stock was $4.4 million based on a $1.27 share price, and as of March 5, 2026, 11,698,919 shares were outstanding.
Synlogic reports it is operating with one full‑time employee focused on evaluating transactions and that ongoing expenses are primarily public‑company costs. The filing emphasizes a large patent and trademark portfolio around its Synthetic Biotic platform but warns that if no strategic deal is completed, the board may consider dissolution and liquidation. Management also discloses a material weakness in internal control over financial reporting related to significant, non‑routine transactions.